GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » Debt-to-EBITDA

OBI Pharma (ROCO:4174) Debt-to-EBITDA : -0.24 (As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is OBI Pharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

OBI Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was NT$75.94 Mil. OBI Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was NT$428.22 Mil. OBI Pharma's annualized EBITDA for the quarter that ended in Jun. 2024 was NT$-2,120.26 Mil. OBI Pharma's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was -0.24.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for OBI Pharma's Debt-to-EBITDA or its related term are showing as below:

ROCO:4174' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.49   Med: -0.16   Max: -0.05
Current: -0.24

During the past 13 years, the highest Debt-to-EBITDA Ratio of OBI Pharma was -0.05. The lowest was -0.49. And the median was -0.16.

ROCO:4174's Debt-to-EBITDA is ranked worse than
100% of 271 companies
in the Biotechnology industry
Industry Median: 1.38 vs ROCO:4174: -0.24

OBI Pharma Debt-to-EBITDA Historical Data

The historical data trend for OBI Pharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OBI Pharma Debt-to-EBITDA Chart

OBI Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.18 -0.20 -0.19 -0.15 -0.49

OBI Pharma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 -0.23 -0.25 -0.25 -0.24

Competitive Comparison of OBI Pharma's Debt-to-EBITDA

For the Biotechnology subindustry, OBI Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OBI Pharma's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OBI Pharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where OBI Pharma's Debt-to-EBITDA falls into.



OBI Pharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

OBI Pharma's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(61.165 + 439.888) / -1018.664
=-0.49

OBI Pharma's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(75.941 + 428.224) / -2120.26
=-0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2024) EBITDA data.


OBI Pharma  (ROCO:4174) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


OBI Pharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of OBI Pharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


OBI Pharma Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Park Street, Room. 1907, 19th Floor, Nangang District, Taipei, TWN, 115
OBI Pharma Inc is part of the healthcare sector. The company and its subsidiaries are engaged in new drug research. Its focus is on the unmet medical need in challenging diseases throughout the world, such as cancer. OBI strives to improve health and the quality of life through cost-effective therapeutics. The Group has four reportable segments, which are the anti-cancer new drug segment, bispecific monoclonal antibody new drug segment, botulinum toxin new drug segment, and CDMO segment.

OBI Pharma Headlines

No Headlines